Back to Results
First PageMeta Content
Pharmacology / Fenfluramine/phentermine / Anti-obesity medication / Phentermine / Fenfluramine / Lorcaserin / Sibutramine / Dexfenfluramine / Rimonabant / Anorectics / Chemistry / Medicine


U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived
Add to Reading List

Open Document

File Size: 686,83 KB

Share Result on Facebook

Company

Arena Pharmaceuticals Inc. / /

Continent

Europe / /

IndustryTerm

obesity treatment / /

MedicalCondition

Suicide-Related Events Cognitive-Related Adverse Events Potential Serotonin-Related Adverse Events Breast Neoplasms / Centrally-acting obesity / Valvular Heart Disease / Depression / standard depression / Long-term obesity / seizures / Pulmonary Hypertension / /

Organization

Metabolism and Endocrinology Products office of New Drugs CDER / U.S. Food and Drug Administration / Division of Metabolism / Endocrinologic and Metabolic Drugs Advisory Committee / /

Person

Julie Golden / /

Position

Medical Officer / M.D. Medical Officer / /

Technology

drug development / /

SocialTag